Expression of TNF inhibitor gene in the lacrimal gland promotes recovery of tear production and tear stability and reduced immunopathology in rabbits with induced autoimmune dacryoadenitis.

Melvin D Trousdale, Zenjin Zhu, Douglas Stevenson, Joel E Schechter, Thomas Ritter, Austin K Mircheff
{"title":"Expression of TNF inhibitor gene in the lacrimal gland promotes recovery of tear production and tear stability and reduced immunopathology in rabbits with induced autoimmune dacryoadenitis.","authors":"Melvin D Trousdale,&nbsp;Zenjin Zhu,&nbsp;Douglas Stevenson,&nbsp;Joel E Schechter,&nbsp;Thomas Ritter,&nbsp;Austin K Mircheff","doi":"10.1186/1740-2557-2-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The most common cause of ocular morbidity in developed countries is dry eye, many cases of which are due to lacrimal insufficiency. Dry eye affects approximately 10 million in the United States, most of whom are women. In the U.S. alone, an estimated 2 million Sjögren's syndrome patients have dysfunctional lacrimal glands and severe dry eye, and there is no satisfactory treatment. These patients would benefit if their lacrimal tissue function could be restored.</p><p><strong>Methods: </strong>The effect of adenovirus-mediated transfer of tumor necrosis factor (TNF)-alpha inhibitor gene on induced autoimmune dacryoadenitis was evaluated in a rabbit model. Soluble transgene protein was detected in tears by ELISA for 7 days following transduction.</p><p><strong>Results: </strong>Two weeks after induction of disease with activated lymphocytes, tear production, as determined by Schirmer testing, was reduced by about 40%, while tear film stability, as measured by tear breakup time (BUT), declined by 43%. Adenovirus-mediated gene therapy using AdTNFRp55-Ig given 2 weeks after disease induction, resulted in the return of tear production to normal levels by week 4. In the treated disease group, tear BUT improved significantly by week 4. Rose bengal scores, an indicator of corneal surface defects, increased after disease induction and declined after gene therapy. In the lacrimal gland, the CD4 to CD8 T cell ratio was 4:1 in the disease group compared to 1:2 in the treated group. Infiltration of T cells and CD18+ cells was reduced approximately 50% after gene therapy.</p><p><strong>Conclusion: </strong>We concluded that therapeutic levels of soluble TNF inhibitor were achieved in the lacrimal gland and on the corneal surface. Anti-inflammatory cytokine gene expression might offer a potential therapeutic modality for the treatment of autoimmune dacryoadenitis, once suitable vectors become available.</p>","PeriodicalId":87189,"journal":{"name":"Journal of autoimmune diseases","volume":"2 ","pages":"6"},"PeriodicalIF":0.0000,"publicationDate":"2005-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1740-2557-2-6","citationCount":"192","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of autoimmune diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/1740-2557-2-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 192

Abstract

Background: The most common cause of ocular morbidity in developed countries is dry eye, many cases of which are due to lacrimal insufficiency. Dry eye affects approximately 10 million in the United States, most of whom are women. In the U.S. alone, an estimated 2 million Sjögren's syndrome patients have dysfunctional lacrimal glands and severe dry eye, and there is no satisfactory treatment. These patients would benefit if their lacrimal tissue function could be restored.

Methods: The effect of adenovirus-mediated transfer of tumor necrosis factor (TNF)-alpha inhibitor gene on induced autoimmune dacryoadenitis was evaluated in a rabbit model. Soluble transgene protein was detected in tears by ELISA for 7 days following transduction.

Results: Two weeks after induction of disease with activated lymphocytes, tear production, as determined by Schirmer testing, was reduced by about 40%, while tear film stability, as measured by tear breakup time (BUT), declined by 43%. Adenovirus-mediated gene therapy using AdTNFRp55-Ig given 2 weeks after disease induction, resulted in the return of tear production to normal levels by week 4. In the treated disease group, tear BUT improved significantly by week 4. Rose bengal scores, an indicator of corneal surface defects, increased after disease induction and declined after gene therapy. In the lacrimal gland, the CD4 to CD8 T cell ratio was 4:1 in the disease group compared to 1:2 in the treated group. Infiltration of T cells and CD18+ cells was reduced approximately 50% after gene therapy.

Conclusion: We concluded that therapeutic levels of soluble TNF inhibitor were achieved in the lacrimal gland and on the corneal surface. Anti-inflammatory cytokine gene expression might offer a potential therapeutic modality for the treatment of autoimmune dacryoadenitis, once suitable vectors become available.

Abstract Image

Abstract Image

Abstract Image

泪腺中TNF抑制剂基因的表达促进了兔诱导的自身免疫性泪腺炎的泪液生成和泪液稳定性的恢复,并减少了免疫病理。
背景:在发达国家,最常见的眼部疾病是干眼症,其中许多病例是由于泪道不全引起的。在美国,大约有1000万人患有干眼症,其中大多数是女性。仅在美国,估计就有200万Sjögren综合征患者患有功能失调的泪腺和严重的干眼症,而且没有令人满意的治疗方法。如果这些患者的泪组织功能能得到恢复,将会受益。方法:采用兔自身免疫性泪腺炎模型,观察腺病毒介导的肿瘤坏死因子(TNF)- α抑制基因转染对自身免疫性泪腺炎的影响。转导后7天,用ELISA法检测泪液中可溶性转基因蛋白。结果:激活淋巴细胞诱导疾病两周后,Schirmer试验测定的泪液产量减少了约40%,而泪液破裂时间(BUT)测定的泪液膜稳定性下降了43%。在疾病诱导后2周使用AdTNFRp55-Ig进行腺病毒介导的基因治疗,在第4周泪液分泌恢复到正常水平。治疗组的泪液BUT在第4周明显改善。作为角膜表面缺陷的指标,Rose bengal评分在疾病诱导后升高,而在基因治疗后下降。在泪腺中,疾病组CD4与CD8 T细胞比值为4:1,治疗组为1:2。基因治疗后,T细胞和CD18+细胞的浸润减少了约50%。结论:我们的结论是,泪腺和角膜表面的可溶性TNF抑制剂达到治疗水平。一旦找到合适的载体,抗炎细胞因子基因表达可能为治疗自身免疫性泪腺炎提供一种潜在的治疗方式。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信